The staging and treatment of multicentric high-grade lymphoma in dogs: a review of recent developments and future prospects.
In recent years, considerable progress has been made in understanding the biology of canine lymphoma with resultant enhanced classification schemes and the possibility of individualised, tailored therapies. However, although complete remission may be achieved using multi-agent chemotherapy, the mortality rate from this neoplasm remains high. This review focuses on the staging of high-grade multicentric lymphoma in the dog, on conventional and novel treatment strategies (including chemotherapy, bone marrow transplantation, radiation therapy and molecular-targeted agents), and on the management of relapsed or refractory cases.
Marconato
Laura
L
Animal Oncology and Imaging Center, 6331 Hünenberg, Switzerland. marconato@aoicenter.ch
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004283:Dog Diseases / Q000145:classification / Q000473:pathology* / Q000628:therapy*; D004285:Dogs; D008223:Lymphoma / Q000145:classification / Q000473:pathology / Q000628:therapy / Q000662:veterinary*; D009367:Neoplasm Staging / Q000662:veterinary; D011379:Prognosis; D012074:Remission Induction; D016896:Treatment Outcome
D000970:Antineoplastic Agents